Caxton Associates LLP Sells 548,559 Shares of Gilead Sciences, Inc. $GILD

Caxton Associates LLP lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 99.7% in the first quarter, Holdings Channel reports. The fund owned 1,441 shares of the biopharmaceutical company’s stock after selling 548,559 shares during the quarter. Caxton Associates LLP’s holdings in Gilead Sciences were worth $201,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of GILD. Brighton Jones LLC lifted its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $215,000. Sivia Capital Partners LLC increased its holdings in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares during the last quarter. Ieq Capital LLC increased its holdings in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC raised its position in Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 674 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: UBS analyst Michael Yee reiterated a Buy rating and maintained a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as sources of durable growth. Michael Yee Reiterates Buy on Gilead
• Positive Sentiment: The earnings preview highlights continued strength in Gilead’s HIV franchise, rising expectations for Yeztugo, and progress in oncology. These businesses could help support revenue growth and investor sentiment if management provides constructive guidance. Gilead to Report Q2 Earnings
• Neutral Sentiment: Gilead’s CAR-T therapies remain established products, but off-the-shelf developers are targeting market segments that approved therapies do not fully address. This could expand the broader CAR-T market while also increasing competitive pressure over time. BMS and Gilead Rule in the CAR-T Space
• Negative Sentiment: Barclays lowered its Gilead price target from $155 to $145 and assigned an Equal Weight rating, signaling more limited near-term upside despite the target remaining above the current trading level. Barclays Gilead Price Target Update
• Negative Sentiment: Analyst previews warn that Gilead may report a decline in second-quarter earnings and does not appear to have the usual combination of positive earnings revisions and estimate-beat indicators. Competitive pressure in Cell Therapy is an additional concern heading into the report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Atea Pharmaceuticals said its hepatitis C combination therapy matched Gilead’s drug in a pivotal Phase 3 trial. If approved, a competing oral regimen could threaten Gilead’s hepatitis C franchise, although commercialization and regulatory risks remain. Atea Hepatitis C Phase 3 Trial

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $132.73 on Thursday. The company has a market capitalization of $164.79 billion, a P/E ratio of 18.08 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The firm’s 50 day simple moving average is $129.68 and its two-hundred day simple moving average is $135.84. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts expect that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 67,000 shares of company stock valued at $8,687,140. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GILD. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Rothschild & Co Redburn decreased their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Royal Bank Of Canada cut their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $157.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.